The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
25 women students to receive internship, training, and mentorship in Life Sciences segment
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Subscribe To Our Newsletter & Stay Updated
